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In the pharmaceutical arena it is agreed that co-crystals form a vital part of the solid-state 
toolbox, allowing the progression of novel compounds through the development pathway to 
patients and improving properties in older medicines. Sadly though, few co-crystals have 
made it to the market in the form of a new licensed product. This displays a disconnect 
between research effort and end product. For some time now it has been possible to 
determine the formation of co-crystals, by a variety of screening and analytical means; 
although it is recognised that there will always be phases that sit in the ‘greyer’ area of the 
salt-co-crystal continuum. It is also possible, with limitations, to predict the formation of co -
crystals in-silico via energetic and structural considerations. So what are the major hurdles 
and missing links, and what are the key structural properties we need to  study to improve the 
success rate? This highlight hopes to address these .  
Introduction  
The term pharmaceutical co-crystal has been with us in earnest 
for the last decade.1 Interest in these solid phases stems from 
their potential to significantly alter the physical properties of an 
active pharmaceutical ingredient (API). There has been 
significant progress in this area with improvements achieved in 
an APIs properties in; dissolution rate, exposure, chemical 
stability, hydration behaviour and tableting performance to 
name but a few.2-6 The potential for API property improvement 
hasn’t been borne out in terms of new molecules entering the 
market as formulated co-crystals. There are a number of APIs 
on the market which on close inspection are indeed formulated 
as co-crystals, not the salts they were originally purported to be; 
these include Depakote and caffeine citrate.7 Overall the 
number of new drug applications (NDAs) for co-crystals 
remains low however. Why is this and what are the missing 
pieces that will mean functional co-crystals can be more widely 
applied in the pharmaceutical context? 
 
Definition and Regulation 
Although the subject of numerous and vigorous debate, 
generally accepted literature definitions of co-crystals within 
the broader context now exist.8 The naming of pharmaceutical 
co-crystals however has a significant bearing on their final 
function i.e. use in patients, regardless of the functional 
advantage served by any phase itself. This is because of the 
regulatory landscape which must be navigated for an API to 
make it onto the market and then into patients, quite rightly as 
these agencies ensure drugs reach patients in a safe and 
reproducible fashion.  
The most recent, and all-encompassing, definition of a 
pharmaceutical co-crystal is as follows:  
 
‘Co-crystals are solids that are crystalline single phase 
materials composed of two or more different molecular and/or 
ionic compounds generally in a stoichiometric ratio which are 
neither solvates nor simple salts.’ 
 
This definition came from the published outcome of the Indo−
U.S. bilateral meeting.9 This meeting and its subsequent 
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outcomes were motivated by publication of the draft FDA 
guidance on co-crystals. This regulatory guidance, now 
progressed from draft status un-changed10, has taken the 
standpoint that co-crystals are; 
 
‘Solids that are crystalline materials composed of two or more 
molecules in the same crystal lattice.’ 
 
In practical terms this means that US FDA has elected to 
classify co-crystals within their framework as dissociable 
“API–excipient” molecular complexes, where the co-former is 
the excipient. This is converse to salts where a new salt is 
considered as a new drug entity. The FDA has taken the 
position that a co-crystal may be treated as a drug product 
intermediate rather than the drug substance. The main 
advantage of this decision is that it retains a less cluttered 
regulatory landscape and it offers the potential of an 
abbreviated new drug application (ANDA), rather than the full 
NDA needed for salts. This decision is potentially inhibitory to 
co-crystal development in novel APIs and a dual edged sword 
for older molecules. For the generics industry although it offers 
a faster route to market approval via the ANDA vs. a novel salt 
it also requires greater screening effort to be undertaken than 
for salts, due to the greater number of potential second entities 
(co-formers) associated with discovering a functional co-
crystal. The number of second entities for use as co-formers is 
potentially unlimited, but as human safety testing is required for 
formulation additives in the pharmaceutical context it is 
normally restrained to the Everything Added to Food in the US 
(EAFUS) or Generally Regarded as Safe (GRAS) list.11 The 
EAFUS list currently holds around 4000 entries of which a 
large proportion are present on the GRAS list and around 2000 
have some toxicity data. The FDA also have an additional list 
which is compiled by the Select Committee on GRAS 
Substances (SCOGS), this list is maintained to analyse the 
health impact, and potential future risks from increases in dose, 
of compounds on the GRAS list. This list contains a more 
modest 332 compounds (260 compounds in category 1, 72 in 
category 2) which are known to be completely safe at current 
levels and may pose no/limited risk if increased in dose. Sadly 
few of these compounds are compatible with co-crystal design 
strategies, so the list remains long. The number of entities 
needed to screen is not however so inhibitory as to override the 
benefits conferred by the option provided by the FDA of the 
ANDA route; screening strategies will be discussed in the 
following section.  
The regulatory delays that can be envisaged from the FDAs 
decision on co-crystal classification will be in those co-crystals 
systems for which definition is not immediately obvious, due to 
ambiguous charge state of one or more components within the 
lattice and the subsequent position on the salt-co-crystal 
continuum.12 Partial charge on the API or co-former, 
temperature dependant proton migration etc. can lead to such 
uncertainty.13 The choice by the FDA to suggest classification 
cut off limits based on 1 pKa unit separation to guide the 
decision of salt vs. co-crystal formation also appears to be 
somewhat spurious as classically the pKa separation ‘rule of 
thumb’ has been that of a separation of 3 pKa units will lead to 
salt formation.13 Further to this co-crystals have been reported 
with a pKa separation of up to 1.5 pKa units and pKa has been 
shown to be a poor indicator of charge state in solids.14 
Depending on the API in question this guidance could be a 
further hindrance to market approval as the classification of co-
crystals as a formulation additive requires inventors to show the 
properties of the parent drug. This leads to the potential need to 
duplicate development effort in novel APIs, especially where 
the free form presents poor development properties, such as a 
difficult to crystallise molecule that had only presented in the 
amorphous form.15 The need for proof of in-vivo dissociation 
could also be of significant impact in this regard.  
 It is therefore envisaged that this guidance will lead to more 
‘lifecycle management opportunities’ and generic applications 
for co-crystals than for applications for new API molecules to 
the market.  
  The regulatory landscape does not detract from the novelty, 
utility and non-obviousness16 of these phases however and as 
such they can still be patented as before. It is not beyond 
comprehension that the future decisions relating to such patents 
will be coloured by the FDA guidance, but at present this has 
not transpired.   
On the whole the authors believe the step by the FDA to release 
guidance to classify co-crystals has been a positive one; with 
certain obvious limitations. Evolution is needed in the 
regulatory definition of hybrid systems, whereby one part of the 
molecular crystals is a complex and the other is a salt,17 but 
previous to this guidance document there was no global 
regulatory direction readily available. Although there are clear 
shortcomings in the philosophical stance of the current 
guidance it does begin to build a regulatory framework in 
which co-crystals can progress to the market; the absence of 
which had been an inhibitory factor to co-crystal development. 
A further potential benefit extending from this guidance is for 
the regulatory acceptance of co-crystallised excipients (i.e. the 
converse of API: API co-crystal blends), since co-crystals are 
simply seen as a formulation. These could beneficially alter the 
physical properties of excipients which have been safety tested. 
This potentially represents a new route for ‘novel’ excipients 
with differentiated function to be used within the marketplace.  
 
 
Efficient screening 
 
In order to go through efficient screening there must first be a 
design strategy. This has largely been focussed on a synthon 
design approach18,19 where a homosynthon has been disrupted 
in preference for a heterosynthon (Figure 1). Historical design 
strategies have largely focussed on simple molecules with a 
single homosynthon and as such have not dealt with the 
competitive interactions within molecules that contain ‘self’ 
heterosynthons. The early work on pharmaceutical co-crystals 
was therefore less immediately applicable in the industrial 
sector where many molecules followed Lipinski’s rules20 and 
had multiple donor and acceptor groups.  
 
  
a) Ibuprofen carboxylic acid homosynthon  
   
  
b) Ibuprofen: nicotinamide carboxylic acid to amide 
heterosynthon 
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Figure 1. Examples of Homo and Heterosynthons  
 
Lipinski’s rules were developed to speed up drug design and 
aid the incorporation of pharmacokinetic considerations into the 
drug discovery process by rational design. These rules are far 
from the only measure of ‘drug likeness’ used in the design of 
novel drug molecules, but they provide a useful indication of 
the number of donors and acceptors likely to be found i.e. 5 H-
bond donors and 10 H-bond acceptors in a molecule of around 
500 Daltons with a LogP of <5. Therefore any screening 
methods should be able to determine the existence of co-
crystals in such molecules.  
 
Screening as an act should allow the efficient removal of 
irrelevant information to allow concentration of effort on the 
important, with the minimal loss of useful information in the 
process. Although distasteful it should be accepted that either a 
proportion of useless information will be retained from the 
screening process or useful information will be lost. In a 
physical form screen the loss of useful information is a greater 
penalty than retention of useless information. Therefore a 
multiple step process is preferable to filter out redundancy 
when dealing with large numbers of compounds, such as will 
be found in a co-crystal screen. A practically sensible screening 
paradigm is outlined in Figure 2. As ever the issue of 
thermodynamically stable and kinetic forms is a dilemma for 
such screening protocols and needs to be considered. The logic 
behind this process is based in the early development 
environment where API material is scarce, typically 500mg-1g 
of material will be available for a screen.  Due to the need to 
maintain a large chemical library of co-formers if in-silico 
screening is avoided, the process is still applicable when 
applied to the later stage environment though.  
 
 
 
 
Figure 2. Co-crystal screening protocol  
 
 
Computationally ‘cheap’ pre-screen 
 
A number of approaches to deal with computational screening 
of co-crystals have been used to great success, in terms of both 
the prediction of the existence and the structure of co-crystals; 
each has relative drawbacks and advantages. These approaches 
have varied in methodology from full structure prediction, 
using anisotropic potentials21, use of summative surface 
interactions via electrostatic potential surfaces and COSMOS-
RS22 to prediction of the H-bond propensity based on 
Cambridge Structural Database (CSD) statistics.23 At the early 
stage of screening full exploration of the GRAS/EAFUS list 
requires screening of circa 2000 co-formers with a vast number 
of conformational permutations and stoichiometric possibilities. 
It is arguable that it is not appropriate to engage in the level of 
effort of full structure prediction for all co-crystal: API 
combinations and their putative stoichiometries at this stage. 
Therefore at the early stage of screening in-silico methods 
which are computationally cheap, but act as accurate pre-
screens are sensible. On a very simplistic level electrostatic 
potential surface approaches ignore crystal lattice 
considerations and follow the basic premise that point charges 
across the surface of the molecule can interact in a pairwise 
fashion, these will form strongest hydrogen bond donor (HBD) 
to strongest hydrogen bond acceptor (HBA) interactions as per 
Etters rules (Figure 3).24 These rules are then sequentially 
followed until all interactions across the surfaces are formed. 
The total energy of the potential solid is then estimated as the 
sum of all likely contacts. This summative energy is then 
compared to the sum of self:self interactions for both 
components. The lower energy, more likely structure, is then 
ranked against others to predict the most likely co-crystals or 
lack of them. The computationally intensive element of such an 
approach is the accurate calculation of the surface. Once the 
surfaces have been calculated the summative energy 
calculations can be achieved very swiftly for a number of 
molecules, conformations and stoichiometries. In future, if 
computing continues to become cheaper and faster at the 
current rate, full structure prediction methodologies would be a 
superior option at this stage.  
 
 
Figure 3. Summative surface energy approach to screening.22 
 
Once such approaches have been undertaken a number of the 
most likely ‘hits’ can be taken to the physical screening stage 
directly. A prudent rationalisation should see screening in the 
region of 50 to 100 systems, but this is obviously dependent on 
the results of the screen. It is logical to apply further predictive 
and empirical approaches at this stage of screening to assess the 
likely applicable functionality of any potential co-crystal 
selected. Discussion of these approaches will be dealt with in 
detail in the subsequent discussion of physical properties.  
 
Physical screen of likely ‘hits’ 
 
A number of excellent reviews and papers have dealt with the 
processes of physical co-crystal screening.25 The weight of 
evidence points to solvent assisted grinding yielding the 
greatest percentage of co-crystal ‘hits’ for the number of 
experiments conducted in the high throughput environment. 
This is due to the inherent propensity of the technique to 
function in the region of ternary phase space where co-crystal 
stability is readily accessible.26 The reaction crystallisation 
method27 also works in this region of phase space with 
excellent results, but is more complex to conduct practically. 
The significant benefit of utilising this approach however is 
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solubility information, which can be used later for 
crystallisation work, and a greater possibility of single crystal 
growth; invaluable for property prediction and definition of the 
phase.  
The drawback of solvent assisted grinding is that it is complex 
to automate in a high throughput fashion i.e. where limited API 
material is available. This has been somewhat inhibitory to its 
use as a screening tool on novel APIs, but the use of ultrasound 
methodologies instead of physical grinding, in a ball mill or 
with a mortar and pestle etc., has opened the door to automated 
robotics platforms.28 This advance has allowed screening in a 
96 well plate and, by utilising significantly smaller API 
quantities, presents another step towards the broader application 
of pharmaceutical co-crystals. This is because further access to 
the early development environment will mean that novel APIs 
can more readily be developed as functional co-crystals. 
Decisions on form selection are generally made relatively early 
in the development pathway to allow bulk chemical processes 
to be appropriately developed and quality assurance to be put in 
place and validated. By miniaturising screening more co-crystal 
information can be available at this stage and therefore more 
co-crystals should be seen in development.  
Post determination of the existence of a phase the most efficient 
means of determining further potential phases (e.g. polymorphs 
and differing stoichiometric compositions), or lack thereof, 
within a system is the Kofler melt fusion approach, which has 
been used to good effect.29 This obviously requires thermal 
stability in the materials under investigation.  
 
Property determination 
 
It is widely quoted30 that 40% of marketed drugs and the 
majority of development compounds have poor solubility. This 
is a significant problem for drug development as the ability for 
the human body to absorb and distribute drugs, steps needed in 
order for them to exert their action, is based on the aqueous 
solubility and in-vivo permeability of the API. If solubility were 
the only problem facing drug development then all drug phases 
should be developed as stabilised amorphous forms, where the 
solubility advantage is guaranteed and generally in the region 
of 1-10 times superior.31 Although this comment is pointedly 
facetious, due to the innumerate disadvantages of such a 
strategy, there is some truth in it.  Solubility however is not the 
only problem in drug development.  Physical and chemical 
stability must be sufficient at those temperatures relevant to 
processing. Flow properties must allow efficient movement of 
bulk powder in processing. Water must be added in wet 
granulation processes and tablet compacts must be made.   In-
vivo performance is essential, but a hurdle that must be 
overcome within the industry is to see co-crystal development 
as a broader church than simply a route to solubility 
improvement. Indeed co-crystal solubility can be lower than 
that of the parent compound.32 In fact of 80 co-crystal systems 
analysed, in 20% of cases worse solubility was seen vs. the 
parent free drug, with one system showing a solubility ratio of 
>3 times worse. Such is the need for improvements in solubility 
it cannot be ignored in any drug development strategy however.  
Therefore co-crystal solubility prediction is essential for 
removing drug development barriers and allowing the efficient 
production of function co-crystal material, further study is 
needed in this area.  
 
Dissolution  
 
One of the earliest signposts that co-crystals would be of 
interest in drug development was from dissolution data.2 The 
spring and parachute model has been discussed widely and is 
applicable to a number of co-crystal systems. This behaviour is 
characterised by a transient improvement in concentration and a 
subsequent drop, normally to the solubility limits of the free 
form in that pH environment. In some systems the improvement 
has been seen to be comparable to the amorphous phase, 
suggesting dissociation, precipitation of amorphous material, 
then eventual recrystallisation.2 Dependent on the ternary 
interactions, on dissolution co-crystal systems have also been 
seen to retain the drug molecule in the solution state (Figure 4). 
Here proof of API: co-former dissociation would presumably 
require greater regulatory scrutiny. The usefulness of either 
class of behaviour is defined by the timescale and extent of any 
improvement in concentration, when considered in the context 
of the intended route of administration. If concentration 
improvements can be maintained over a bio-relevant timescale 
then it is strong evidence that a co-crystal phase will possess 
useful function.  
In oral delivery the majority of reproducible drug absorption is 
from the small intestine where the absorptive surface is large 
and the pH environment is generally in the region of pH 6.8.33 
Here lies another advantage of co-crystals. In neutral API 
molecules, where the dissolution behaviour is not driven by pH 
speciation, one can tailor the release by use of an ionisable co-
former.34 Further to this the use of formulation additives can 
inhibit free form nucleation after dissociation of the co-crystal, 
providing a ‘parachute’ where one does not naturally exist,35 
micellar approaches have also been employed to similar end.36 
These results highlight an area that requires more study in co-
crystals and engineering systems which encompass tailored 
nucleation inhibitors and surfactants as co-formers is an 
exciting possibility. In such theoretical systems incongruent 
saturation in the ternary environment would be of benefit, as 
fast dissociation would lead to a maintained supersaturated 
state, allowing more drug to be absorbed via the intended route.  
 
 
 
Figure 4. Comparison of dissolution of the individual components 
and the co-crystal of ibuprofen: nicotinamide. †  
 
The oral drug delivery route represents around 70% of 
medicines in use, however the dissolution and dissociation 
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behaviours of co-crystals have so far been poorly explored in 
non-oral delivery routes. In the instance of ocular and nasal 
delivery it can be envisaged that there is significant 
development opportunity based on their dissociation 
behaviours. Therefore the major hurdle, which must be 
overcome with respect to dissolution, is the development of co-
crystal approaches beyond oral therapy areas, a superior 
understanding of co-former structure to function relationships 
and uses in targeted drug delivery approaches.  
 
Resistance to hydration  
 
Although physical and chemical stability on storage is of great 
utility from the perspective of shelf life, and a primary driver 
for understanding moisture sorption behaviour, many 
pharmaceutical processes also require modification of the 
humidity environment. Indeed processes such as wet 
granulation often require water to be added directly. This is a 
significant problem in those systems that are poorly stable to 
high humidity or disassociate readily.   
Early results with caffeine showed that co-crystals could be of 
benefit here.6 The moisture sorption behaviour of ibuprofen and 
nicotinamide has been reported and has been shown to be 
low.37 In all cases the figure of <1% moisture uptake would 
represent low levels of moisture sorption. This behaviour is also 
replicated in the subsequent co-crystal37 (Figure 5).  
Here co-crystals show a great advantage over salts. The 
ibuprofen sodium salt, the most widely marketed form, forms a 
di-hydrate (approximately 13.5% total mass is water) and 
before formation of this hydrate phase is highly hygroscopic.38 
As such during manufacturing processes the moisture 
environment must be controlled, this can add significant 
expense to the development of pharmaceutical phases and be an 
inhibitory factor to phase development, by increasing drying 
time etc.  
 
 
 
 
Figure 5. Moisture sorption in the ibuprofen: nicotinamide co-
crystal system.† Loss of moisture in the first cycle is attributed 
to a proportion of amorphous content produced from grinding.  
 
A high degree of moisture absorption is a property, which also 
leads to stickiness and poor powder flow. This is another 
property that co-crystals have been seen to improve.39 This very 
simple property can have a large impact on the production of all 
solid dosage forms, for example tablets and capsules. 
Knowledge of structure/function correlation between co-fomer 
and co-crystal would be a significant advantage in this area too.  
 
 
Compaction behaviours 
 
The tableting behaviour of an API can be altered by 
formulation approaches, but if high drug loading is needed, in 
order to produce once a day formulations for example, the 
tableting behaviour of the drug phase becomes increasingly 
important. Co-crystallisation has been shown to both improve 
and worsen tableting performance.6,39 These behaviours have 
been rationalised by the crystal structure of the co-crystal vs. 
the parent drug. In the non-steroidal anti-inflammatory drugs 
(NSAIDs) ibuprofen and flurbiprofen improvements in 
tableting performance vs. the parent were seen when co-
crystallised with nicotinamide.37 Tablet strength, i.e. the tensile 
strength of the compressed powder, is gained from interactions 
between particles of a given material. Bonding area between 
particles dictates this strength and it has been established that 
plastic deformation of particles, along with size reduction by 
brittle fracture, is critical in the formation of a large bonding 
area by compaction.40 Slip planes within structures mean that 
they have lower yield strength, are more plastic and therefore 
form stronger more dense compacts. Such slip planes can be 
seen in the crystal structures of both the ibuprofen and 
flurbiprofen co-crystals (Figure 6).  
 
 
 
a) R/S Ibuprofen: nicotinamide co-crystal viewed down the a-
axis.  
 
b) R/S flurbiprofen: nicotinamide co-crystal† viewed down the 
c-axis.  
Figure 6. Slip planes in the R/S ibuprofen (a) and R/S 
flurbiprofen (b) : nicotinamide co-crystal structures. Slip planes 
are highlighted in red.  
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Both structures display clear planes along which limited 
bonding can be seen; both in terms of H-bonding and weaker 
bonding forces. Thus reducing the yield strength of the 
materials and improving compaction behaviours. Of the two 
parent molecules R/S ibuprofen showed significantly superior 
tableting performance, again slip planes are clearly evident in 
the structure, this is not the case in the stable polymorph of 
flurbiprofen (see Figure 7) where offset π-π stacking allows 
bonding in all planes.  
 
 
 
a) RS Ibuprofen (IBPRAC) viewed down the b-axis. The slip 
plane is highlighted in red.  
 
b) RS flurbiprofen (FLUBIP01) viewed down the a-axis.  Left 
image is without Van der Waals interactions shown, right 
image with.  
Figure 7. Crystal structures of ibuprofen (IBPRAC) (a) and 
flurbiprofen (b)  
 
It should be noted that, a crystal structure of nicotinamide with 
naproxen, another non-steroidal anti-inflammatory drug 
(NSAID), has been identified (PAMQAX). Sadly no tablet 
formation or compression data is available for this phase. This 
co-crystals structure possesses comparable H-bond motifs and 
slip planes to the API: nicotinamide co-crystals displayed here. 
Therefore, although potentially biased by the small size of the 
dataset, improved tableting behaviour can been seen across a 
series of similar drug molecules when using the same co-former 
(nicotinamide). Nicotinamide possesses good tableting 
properties and is a brittle material.37 Not all co-formers are the 
as useful in this arena and broader consideration of the property 
which is required from a co-crystal is always recommended.  
If similar results are borne out in larger datasets physical 
property prediction of co-crystals will become more feasible 
across homologous series. This is potentially very important 
when considering the way in which drug development and 
discovery activities are usually conducted i.e. with a target 
based focus. These results show that there is potential for a 
reduction of screening effort across a set of discovery 
compounds and realisation of preferred co-formers for 
particular purposes, if adequate structure property relationships 
can be identified.  
 
 
Crystallisation and scale up 
 
Efficient production approaches are essential if co-crystals are 
to become more widely utilised. Classic solution crystallisation 
approaches are the most industrially applicable due to the 
habitual use of such technology across the globe and indeed 
have been used to good effect.15 Within this conventional 
approach the issues imposed by the phase diagram41 for the 
chosen solvent: co-fomer: API ternary system, need careful 
consideration; from initial solid form isolation through to scale 
up activities. The impact of solvent choice on the isolated 
stochiometric composition, in relation to solution 
stoichiometric composition,42 has  significant implications. 
Solubility differences of 2 times would mean that half of the 
more soluble component would always be lost to the solvent. 
This could obviously be recovered, but at a cost. This highlights 
again the importance of advances in solubility prediction.32 
Solubility product (SP) models have been applied to systems 
under specific conditions with a great deal of success, but 
further investigation into self-seeding phenomena43 and 
continued development of solubility models, to address the 
working limitations of SP models, is needed. These points 
require further work in order to draw a line on the debate to use 
the solution crystallisation route.  Consequently, either 
proceeding on this route or making significant moves away 
from such technology, although possible, will represent the 
need for significant investment across the industry and 
academia; especially if continuous processes are to be 
considered.  
Solvent crystallisation methods have been utilised to produce 
co-crystals from a thermal inject printer.45 Such technology 
could have many exciting applications in the production of 
multiple drug tablet platforms or to produce tailored modified 
release systems based on a patients phenotypical variance; the 
latter could be achieved by utilising mixtures of the free drug 
and one or more co-crystals. It is suggested by the authors of 
this work that this technology could be used for early 
development screening too.  
Other techniques have been used for the production of co-
crystals and would be compatible with continuous processing 
strategies. Extrusion represents the most studied bulk process 
for co-crystal manufacture and significant advances have been 
made using IR as a process analytical tool (PAT).46 Freeze 
drying is another technology that has been shown to readily 
apply to co-crystallisation.47 Like co-grinding the co-crystal 
product is produced by transfer through an amorphous phase. 
This highlights the need for adequate understanding of 
crystallisation kinetics in co-crystal systems, regardless of the 
route of production. Supercritical fluid technology and gas anti-
solvent methods have been used to good effect.48 Microwave 
synthesis has also been used for the production of co-crystals.49 
Microwave synthesis failed to produce changes, from the 
starting components to co-crystal material, in the caffeine: 
maleic acid system without solvent, the technology has shown 
excellent promise as a continuous manufacturing technology 
with the aid of solvent however.  
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Conclusions 
 
Although there is a weight of evidence, which continues to 
build, for the use of pharmaceutical co-crystals they still 
represent a greater cost and perceived risk to development than 
a comparable salt. The future is bright though and in instances 
where no salt can be made, or where those explored are 
unsuitable, co-crystals present a very real and viable option for 
development. As screening and selection strategies should 
encompass the breadth of solid forms and soft matter with time 
even in instances where a salt is possible co-crystals may well 
be selected; once structure to function relationships have been 
thoroughly explored. Moves away from arguments based 
simply on oral delivery and GI dissolution behaviour are 
needed along with computational screening approaches to 
utilise the full gamut of co-crystal possibility. Robust analysis 
of co-crystal: API: co-former structure property relationships, 
and dissociation behaviours, are also required to optimise 
screening and manufacturing efficiency. Once these have been 
investigated functional co-crystal material should be more 
readily accessible as a realistic option to deliver medicines to 
patients and improve lives.   
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Experimental† 
 
Dissolution 
 
Dissolution was performed using the rotating disc method, and 
run at 37°C in 500mL of phosphate buffer at pH 7; which 
mimics the pH environment of the lower intestine. The discs 
were made from compacts of 150mg of pure component or co-
crystal, which were compressed at a pressure of 1 metric tonne 
for 1 minute. In-situ UV probes were used to measure the 
concentration within the solution media (in an N = 2 study). 
These probes were calibrated with 1mg/mL aqueous methanol 
solutions of the respective solids. The dissolution concentration 
was then calibrated against the λmax of the various adducts 
(260nm ibuprofen, 276nm nicotinamide) allowing good 
mapping of concentration against time. 
 
Dynamic Vapour Sorption 
 
DVS was performed using the surface Measurement Systems 
(SMS) Advantage dynamic vapour sorption (DVS) instrument 
utilising a set of sorption, desorption cycles on 10.65mg of 
sample in 10% humidity steps. Samples were weighed until of 
consistent mass at a given humidity.  
 
Crystal growth 
 
Single crystals were grown from a seeded mixture of 
flurbiprofen (R/S) (0.614 mmol) and nicotinamide (3.7 mmol) 
in 500 μL of ethanol, temperature cycled utilising a Grant LTC 
6-30 water bath. The sample was sequentially cooled and 
heated in a saw-toothed cycle from 288K to 283K over 50 hrs. 
 
Crystallography† 
 
 
Figure 8. Flurbiprofen and nicotinamide 
 
C21H20FN2O3, M = 367.39, Monoclinic, P21/c, a = 27.459(1) Å, b = 
5.6654(2) Å, c = 11.4275(5) Å,  = 92.250(2)°,  =  = 90°, V = 
1776.4(1) Å3, T = 120(2) K, Z = 4,  (Mo K) = 0.100 mm-1, 17171 
reflections measured, 3958 unique (Rint = 0.0651) which were used 
in all calculations. The final wR2 was 0.1448 (all data) and R1 was 
0.0543 (I ≥ 2(I)). 
 
References 
 
1 S.L. Morissette,  Advanced Drug Delivery Reviews. 2004, 56 
(3), 275.; O. Almarsson, M. J. Zaworotko, Chemical 
communications, 2004, 17, 1889.; O. Almarsson, M.L. 
Peterson, M. Zaworotko, Pharmaceutical Patent Analyst, 
2012, 1 (3), 313.  
2 S. L. Childs, L. J. Chyall, J. T. Dunlap, V. N. Smolenskaya, 
B.C. Stahly, G.P. Stahly,  J. Am. Chem. Soc., 2004, 126, 
13335.; H. Babu and A. Nangia, Cryst. Growth Des., 2011, 11, 
2662.; J.W. Steed, Trends in Pharmacological Sciences, 2013, 
34 (3), 187.; R. Thakuria, A. Delori, W. Jones, M.P. Lipert, L. 
Roy, and N. Rodriguez-Hornedo, International Journal of 
Pharmaceutics, 2013, 453(1), 101.  
3 D.P. McNamara, S.L. Childs, J. Giordano, A. Iarriccio, J. 
Cassidy, M.S. Shet, R. Mannion, E. O’Donnell and A. Park, 
Pharmaceutical Research, 2006, 23 (8), 1888 
4 V.R. Vangala, P.S. Chow, and R.B.H. Tan, CrystEngComm, 
2011, 13, 759. 
5 A.V. Trask, W. D. S. Motherwell, and W. Jones Crystal 
Growth & Design, 2005, 5 (3), 1013. 
6 S. Karki,  .  ri  i , L.  abian, P.R. Laity,  . M. Day and . 
Jones, Adv. Mater.,  2009, 21, 3905. 
7 G. Petru evski, P. Naumov, G. Jovanovski, Ng, S. Weng, 
Inorg. Chem. Commun. 2008, 11, 81.; S. Karki, T.  ri  i , . 
Jones, W. D. S. Motherwell, Mol. Pharmaceutics, 2007, 4, 
347.  
8 M.C. Etter and T.W. Panunto, Journal of the American 
Chemical Society, 1988, 110 (17), 5896.; G.R. Desiraju, 
CrystEngComm, 2003. 5, 466.; J.D. Dunitz, CrystEngComm, 
2003, 5, 506.; N. Shan and M. J. Zaworotko, Drug Discovery 
Today, 2008, 13, 440; W. Jones, W. D. Motherwell and A. V. 
Trask, MRS Bull., 2011, 31, 875. 
9 S. Aitipamula, R. Banerjee, A. K. Bansal, K. Biradha, M. L. 
Cheney, A. R. Choudhury, G. R. Desiraju, A. G. Dikundwar, 
R. Dubey, N. Duggirala, P. P. Ghogale, S. Ghosh, P. K. 
Goswami, N. R. Goud, R. K. R. Jetti, P. Karpinski, P. Kaushik, 
D. Kumar, V. Kumar, B. Moulton, A. Mukherjee, G. 
Mukherjee, A. S. Myerson, V. Puri, A. Ramanan, T. 
Rajamannar, C. M. Reddy, N. Rodriguez-Hornedo, R. D. 
Rogers, T. N. G. Row, P. Sanphui, N. Shan, G. Shete, A. 
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 2012 
Singh, C. C. Sun, J. A. Swift, R. Thaimattam, T. S. Thakur, R. 
K. Thaper, S. P. Thomas, S. Tothadi, V. R. Vangala, P. 
Vishweshwar, D. R. Weyna and M. J. Zaworotko, Cryst. 
Growth Des., 2012, 12, 2147. 
10 Center for Drug Evaluation and Research. April 2013. 
Guidance for industry: Regulatory Classification of 
Pharmaceutical Cocrystals. Rockville, Maryland: United States 
Food and Drug Administration. 
11 The EAFUS list is currently available on the FDA web site at 
http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?r
pt=eafusListing&displayAll=true. Accessed Jan 8th, 2014. The 
SCOGS list is available at 
http://www.accessdata.fda.gov/scripts/fcn/fcnNavigation.cfm?r
pt=scogsListing. Accessed Jan 8th, 2014.  
12 S. L. Childs, G. P. Stahly and A. Park, Mol. Pharmaceutics, 
2007, 4, 323.  
13 H.G. Brittain, Journal of Pharmaceutical Sciences, 2012, 102 
(2), 311. 
14 C.C. Seaton, CrystEngComm, 2011, 13, 6583.  
15 P. Bowles, S.J. Brenek, S. Caron, N. M. Do, M.T. Drexler, S. 
Duan, P. Dube , E.C. Hansen, B.P. Jones, K.N. Jones, T.A. 
Ljubicic, T.W. Makowski, J.Mustakis, J.D. Nelson, M. Olivier, 
Z. Peng, H.H. Perfect, D.W. Place, J.A. Ragan, J.J. Salisbury, 
C.L. Stanchina, B.C. Vanderplas, M.E. Webster, and R. M. 
Weekly, Organic Process Research and Development, 
doi.org/10.1021/op4002802. 
16 A. Trask, Molecular Pharmaceutics, 2007, 4 (3), 301. 
17 C.C. Seaton, I.J. Scowen, N. Blagden,  CrystEngComm, 2009, 
11 (9). 1793.  
18 G. R. Desiraju, Angew. Chem., Int. Ed. Engl., 1995, 34, 2311. 
19 S. Fleischman, S. Kuduva, J. McMahon, B. Moulton, R. 
Walsh, N. Rodriguez-Hornedo and M. J. Zaworotko, Cryst. 
Growth Des., 2003, 3, 909–919.; C. B. Aakeroy, B. M. T. 
Scott, M. M. Smith, J. F. Urbina and J. Desper, Inorg. Chem., 
2009, 48, 4052.; C. B. Aakeroy and D. Salmon, 
CrystEngComm, 2005, 7, 439–448.; B. R. Bhogala, S. 
Basavoju and A. Nangia, CrystEngComm, 2005, 7, 551.; B. R. 
Sreekanth, P. Vishweshwar and K. Vyas, Chem. Commun., 
2007, 2375. 
20 C.A. Lipinski, Drug Discovery Today: Technologies, 2004, 1 
(4), 337.  
21 N. Issa, P. Karamertzanis, G. Wellch, S. Price, Cryst. Growth 
Des., 2009, 9 , 442.; P. Karamertzanis, A. Kazantsev, N. Issa, 
G. Wellch, C. Adjiman, C. Pantelides, S. Price, J. Chem. 
Theory Comput., 2009, 5, 1432.; S. Chan, J. Kendrick, M. A. 
Neumannc and F.J.J. Leusen, CrystEngComm, 2013, 15, 3799.  
22 D. Musumeci, C. Hunter, R. Prohens, S. Scuderi, F. McCabe, 
Chem. Sci., 2011, 2, 883.; Yu. A. Abramov, C. Loschen, A. 
Klamt, J. Pharm. Sci., 2012, 101, 3687.; T. Grecu, C.A. 
Hunter, E.J. Gardiner, and J.F. McCabe, Crystal Growth & 
Design, 2014, 14 (1), 165. 
23 Peter Galek, Elna Pidcock and Peter Wood, CSD Solid Form 
Suite: addressing Key Issues in Solid State Development, 
White Paper, 2011.  
24 M.C. Etter, Journal of the American Chemical Society, 1982, 
104(4), 1095.  
25 A. Newman, Org. Process Res. Dev. 2013, 17, 457.; K. Fucke, 
S. A. Myz, T.P. Shakhtshneider, E.V. Boldyreva and U.J. 
Griesser, New J. Chem., 2012, 36, 1969.; A. Alhalaweh, S. 
George, S. Basavoju, S.L. Childs, S.A.A Rizvi and S.P. 
Velaga, CrystEngComm, 2012, 14 (15), 5078.; 
26 A. Delori, T.  ri  i  and .  ones, CrystEngComm, 2012, 14, 
2350.  
27 N. Rodríguez-Hornedo, S.J. Nehm, K.F. Seefeldt, Y. Pagan-
Torres and C.J. Falkiewicz,  Mol Pharm., 2006, 3(3), 362.  
28 V. Luu, J. Jona, M.K. Stanton, M. L. Peterson, H.G. Morrison, 
K. Nagapudia, and H. Tan, International Journal of 
Pharmaceutics, 2013, 441,  356.  
29 D.  .  erry,  .  . Seaton, .  legg, R. .  arrington, S.  . 
 oles, P.  .  orton, M.  .  ursthouse, R. Storey, .  ones,  . 
 ri  i  and  .  lagden, Cryst. Growth Des., 2008, 8, 1697.; O. 
Henck, J. Bernstein, A. Ellern and R. Boese, J. Am. Chem. 
Soc., 2001, 123, 1834.; N. Zencirci, T. Gelbrich, V. 
Kahlenberg and U. J. Griesser, Cryst. Growth Des., 2009, 9, 
3444.  
30 H.D. Williams, N.L Trevaskis, S.A Charman, R.M Shanker, 
W.N. Charman, C.W. Pouton and C.J. Porter, 
Pharmacological Reviews, 2013, 65 (1), 315 
31 B. Hancock & M. Parks, Pharm. Res., 2000, 17 (4), 397.  
32 G.L. Perlovich, J. Chem. Thermodyn. (2013), 
http://dx.doi.org/10.1016/j.jct.2013.10.030 
33 D. Hörter and J.B. Dressman, Adv. Drug Del. Rev,  2001, 46, 
75.  
34 L. S. Reddy, S. Bethune, A. Jayasankar, and N. Rodríguez-
Hornedo, Crystal Growth and Design, 2009, 9: 378. 
35 S.L. Childs, P. Kandi and S. Reddy Lingireddy, Mol. 
Pharmaceutics, 2013, 10, 3112.  
36 N. Huang and N. Rodríguez-Hornedo, Crystal Growth & 
Design, 2010, 10 (5), 2050. 
37 S.F. Chow, M. Chen, L. Shi, A.H.L. Chow and C.C. Sun, 
Pharm Res, 2012, 29, 1854.  
38 Y. Zhang and D.J.W. Grant, Acta Cryst., 2005, C61, m435. 
39 M. Baldrighi,G. Cavallo, M.R. Chierotti, R. Gobetto, P. 
Metrangolo, T. Pilati, G.  Resnati, and G. Terraneo. Mol. 
Pharmaceutics, 2013, 10, 1760.  
40 C.C. Sun, H. Hou, Cryst Growth Des., 2008, 8 (5), 1575.; E.N. 
Hiestand., J Pharm Sci., 1985, 74, 768. ; E.N. Hiestand, 1991., 
Int. J. Pharm., 1991,  67, 217. 
41 JW Nielson and RR Monchamp in Refectory Materials, ed. J.L 
Margrave, Academic Press, 1970, ch. I, pp. 32-34.; D.J. Good, 
N. Rodriguez-Hornedo, Crystal Growth & Design, 2009, 9 
(5), 2252. 
42 C.C. Seaton, A. Parkin, C.C. Wilson, and N. Blagden, Cryst. 
Growth Des., 2009, 9 (1), 47. ; S.J. Nehm, B. Rodriguez-
Spong, and N. Rodriguez-Hornedo, Crystal Growth & Design, 
2006, 6 (2), 592.  
43 Blagden (self) R. J. Davey, N. Blagden, S. Righini, H. Alison, 
M.J. Quayle, and S. Fuller, Crystal Growth and Design, 2001, 
1 (1), 59.  
44 M. Quayle, R. Davey, N. Blagden, H.F. Lieberman, Cryst. 
Eng. Comm. 2002; 4: 257.  
Journal Name ARTICLE 
 
This journal is © The Royal Society of Chemistry 2012 J. Name., 2012, 00, 1-3 | 9  
45 A.B.M. Buanz, R. Telford, I.J. Scowen and Simon Gaisford. 
CrystEngComm, 2013, 15, 1031. 
46 A.L. Kelly, T. Gough, R.S. Dhumal, S.A. Halsey and A. 
Paradkar, International Journal of Pharmaceutics, 2012, 426, 
15.; R.S. Dhumal, A.L. Kelly, P. York, P.D. Coates and A. 
Paradkar, Pharm Res, 2010, 27, 2725.  
47 M.D. Eddleston, B. Patel, G.M. Day and W. Jones, Cryst. 
Growth Des., 2013, 13, 4599.  
48 L. Padrela, M.A. Rodrigues, S.P. Velaga, H.A. Matos and E.G. 
De Azevedo, Eur J Pharm Sci., 2009, 38(1), 9. ; C.A. Ober and 
R.B. Gupta1, AAPS PharmSciTech, 2012, 13 (4), 1396.  
49 S. Pagire, S. Korde, R. Ambardekar, S. Deshmukh, R. Charan 
Dash, R. Dhumal and A. Paradkar, CrystEngComm, 2013,15, 
3705. 
 
